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It is reported by primatologists that Great 
Apes utilize various plants for their healing 
effects (Sumner, 2000; Halberstein, 2005). 
Chimpanzees swallow the leaves of several 
plants including leaves of Ficus exasperata, 
which contain a potent psoralen that kills 
nematode worms. Leaves are not the only 
plant parts that might be used by animals. 
Chimpanzees also chew the bitter pith 
from young shoots of the species Vernonia 
containing steroid-glycosides interfering 
with the life cycle of trematodes causing 
schistosomiasis. Interestingly, Vernonia is 
known in Tanzania as mujonso (the bitter 
leaf tree). Natives of Tanzania are crushing 
Vernonia leafs and twigs in cold water to 
treat pain associated with intestinal para-
sites. There are several other examples of 
the use by Humans of extracts of plants 
also used by Great Apes. This is not surpris-
ing in view of the encyclopedic knowledge 
collected by Nganga through traditional 
observation of their natural environment 
(Godfraind, 2010). It is likely that the quest 
for medicines is an early activity of human-
ity. Indeed oldest written documents report 
on medicines preparations initially orally 
transmitted from generation to generation. 
For instance the Ebers papyrus, one of the 
oldest known medical works dated about 
1550 BC, is a compilation of medical texts 
including remedies originated years ago. It 
is not the purpose of this paper to review 
history of empirical discoveries of medi-
cines mostly prepared from plants. They 
occurred in various continents as shown 
by collections of materia medica reported 
by Chinese, Greek and Latin authors in the 
BC era (Wang et al., 2007). Interestingly, in 
the nineteenth century, François Magendie 
and Claude Bernard, studying alkaloids 
extracted from traditional poisons from 
Africa or South America, observed that 
the action of those agents had a precise 
anatomical localization (Lazorthes and 
Campan, 1984). Those studies mark the 
birth of Experimental Pharmacology at 
the time of chemical purification of active 
molecules from plant extracts (Godfraind, 
2007). A subsequent step has been the 
transformation of natural molecules, native 
of different regions, into better-tolerated 
preparations such as aspirin obtained by 
acetylating sodium salicylate. During the 
first half of the twentieth century, Ernest 
Fourneau and his Colleagues (including 
Daniel Bovet and Frederico Nitti) of the 
Pasteur Institute in Paris produced deriva-
tives of adrenaline, acetylcholine and hista-
mine as well as of their natural antagonists, 
giving rise to study of their pharmaco-
logical properties (Bovet and Bovet-Nitti, 
1948). This research trend culminated in 
Sir James Black’s discoveries of β-blockers 
and H2 antagonists (Black, 1979). Some of 
those molecules have been used in experi-
ments designed to verify Clark’s receptor 
theory leading to the observation that 
the action of drugs does obey the law of 
mass action (Kenakin, 2004). The devel-
opment of quantitative bioassay by J.H. 
Burn (Vane, 1982) and the initiation of 
analytical pharmacology by H.O. Schild 
(Arunlakshana and Schild, 1959) paralleled 
studies reported above. They proved to be 
useful for the finding of other pharmaco-
logical principles including ACE inhibitors 
(Cushman and Ondetti, 1991) and Calcium 
Channel Blockers (Godfraind et al., 1986), 
an illustration of the role of Pharmacology 
in drug discovery (Fredholm et al., 2002).
Despite huge investment in novel tech-
nology and attempts to streamline the drug 
discovery process, the last 10 years or so have 
not seen any increase in the number of new 
pharmacological entities that have reached 
the market. This low rate of success is one of 
the reasons why the estimated cost for RD of 
a new drug is so very high, around 900 mil-
lions Euro (Donnelly and Jehenson, 2005), 
the other reason is that costs increase faster 
than inflation. The constantly increasing 
cost for research and development and the 
relatively steady trickle of new drugs to the 
market has been known for quite some time. 
This has obviously worried drug industry.
Attempts to correct the imbalance have 
included various purportedly cost-cutting 
mergers and the pursuit of blockbuster 
drugs. New lead-identification method-
ologies such as combinatorial chemistry 
and high-throughput screening have been 
integrated into pharmaceutical research. 
At the end of the twentieth century from 
1950 onwards, a period of pharmaceutical 
success in drugs for cardiovascular, gastro-
enterological and neurological diseases, 
novel chemical entities were evaluated on 
composite models in organ bath or test tube 
before going to whole animals or Humans. 
Expert teams could reach production and 
evaluation of about 2000 molecules per 
year. For the new methodologies, compos-
ite models have been abandoned to study 
2000 compounds per day, which means 
400,000 per year. From 2000, robots oper-
ate up to 105 tests or even more per day on 
cloned targets. These measures have caused 
a remarkable uniformity in industry some-
thing that is further enhanced by the use 
of essentially identical research techniques 
(Schirlin et al., 2007). The clear lack of suc-
cess of these managerial techniques must 
be recognized. Would the introduction of 
concepts such as “translational medicine” 
or “systems biology” bring a proper evalu-
ation of those molecules designed at ran-
dom and tested on artificial targets? The 
hypothesis that understanding of biological 
systems will somehow emerge from huge 
arrays of data and sophisticated statisti-
cal analyses does not take into account the 
complexity of natural processes. The chase 
of universal blockbuster drugs has found 
its limits in the field of cancer therapy 
with monoclonal antibodies, when it was 
observed that trastuzumab was active in 
breast cancers expressing HER2 (Crowder 
et al., 2004), therefore requiring a genomic 
classification of patients. Quite recently, 
studies on BRAF-mutant melanoma (Bollag 
et al., 2010) emphasized pharmacogenomic 
approach of patients’ therapy. This rein-
forces the need for developing translational 
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in Pharmacology). Here academia and 
industry should  cooperate and this must 
be done at a translational level, in a two-
way road (Marincola, 2003). Frontiers in 
Pharmacology Journals welcome publica-
tions related to those novel aspects of drug 
research as well as analytical studies of clas-
sically used drugs.
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medicine (Godfraind, 2007). From the Basic 
Pharmacology point of view, molecular 
design from target structure looks more 
rational than a random search in a library 
of 106 compounds. But we should not forget 
from where we are coming. Indeed, natural 
substances are not only active by themselves 
but they appear to be lead compounds for 
a large family of medicines, a nice example 
is the large family of derivatives of penicil-
lin. According to some estimates, Earth is 
home for about 250,000 different species 
of plants, for up to 30 million species of 
insects and for an equal number of species 
of fungi, algae, and bacteria. However, when 
not provided by empirics, very little number 
of these organisms has been tested to see 
whether they harbor bioactive substances. 
Recently important small molecules such 
as artemisinin and shikimic acid, the pre-
cursor of oseltamivir (Tamiflu®), have been 
purified from natural products of mille-
nary use in China. Screening of the huge 
library of natural products is an immense 
task but it will further Pharmacology. Since 
we are entering the time of the omics and 
of personalized medicine, finding cellular 
targets of small molecules is a major break-
through in drug discovery as illustrated by 
the case of cyclo-oxygenase target of aspi-
rin (Vane et al., 1990). The development 
of biomarkers for predictive toxicity and 
for identifying the nature of diseases and 
their evolution under drug treatment is 
mandatory (see Grand Challenges of Chief 
Editors of Specialty Journals of Frontiers 
